Predictable threats to public health through delaying universal access to innovative medicines for Hepatitis C: A pharmaceutical standpoint

by Rafaella Ravinetto, Anja De Weggheleire, Thomas P.C. Dorlo et al.
Tropical Medicine & International Health – Accepted manuscript online: 27 September 2016

12 pp. 162 kB
http://onlinelibrary.wiley.com/doi/10.1111/tmi.12784/epdfcover

The new interferon-free direct-acting antiviral (DAAs) treatment combinations have the potential to provide a cure for Hepatitis C Virus patients and stop the pandemic, but their high prices keep treatment out of reach for most patients in Low- and Middle-Income countries, and the access strategies voluntarily put in place by some pharmaceutical companies remain insufficient to provide treatment to all those in need. Market incentives should be in place to push manufacturers to obtain WHO Prequalification and/or registration by a Stringent Regulatory Authority, so as to allow the launch of large-scale governmental (and/or humanitarian) treatment programs with affordable, quality-assured medicines. This is an urgent issue that needs to be addressed now in order to fight an important disease that could be cured and probably eliminated with adequate resources.

(Visited 38 times, 1 visits today)
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.